Matter, Matthias S.
Terracciano, Luigi M.
Ng, Charlotte K.Y.
Heim, Markus H.
- Journal Article
Hepatocellular carcinoma (HCC) is the most common primary liver cancer and the second most frequent cause of cancer-related mortality worldwide. The multikinase inhibitor sorafenib is the only treatment option for advanced HCC. Due to tumor heterogeneity, its efficacy greatly varies between patients and is limited due to adverse effects and drug resistance. Current in vitro models fail to recapitulate key features of HCCs. We report the generation of long-term organoid cultures from tumor needle biopsies of HCC patients with various etiologies and tumor stages. HCC organoids retain the morphology as well as the expression pattern of HCC tumor markers and preserve the genetic heterogeneity of the originating tumors. In a proof-of-principle study, we show that liver cancer organoids can be used to test sensitivity to sorafenib. In conclusion, organoid models can be derived from needle biopsies of liver cancers and provide a tool for developing tailored therapies. Show more
Journal / seriesCell Reports
Pages / Article No.
Subjecthepatocellular carcinoma; cholangiocellular carcinoma; liver; patient-derived organoids; patient-derived xenografts; needle biopsy; Biobank; genetic heterogeneity; drug response
Organisational unit09492 - Schwank, Gerald (ehemalig) / Schwank, Gerald (former)
09492 - Schwank, Gerald (ehemalig) / Schwank, Gerald (former)
609883 - Mechanisms of Evasive Resistance in Liver Cancer (EC)
MoreShow all metadata